CleanTech Acquisition (CLAQ) Competitors

CleanTech Acquisition (NASDAQ:CLAQ) and Ekso Bionics (NASDAQ:EKSO) are both small-cap companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, community ranking, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Which has higher earnings and valuation, CLAQ or EKSO?

CleanTech Acquisition has higher earnings, but lower revenue than Ekso Bionics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CleanTech Acquisition	N/A	N/A	-$600K	N/A	N/A
Ekso Bionics	$17.93M	0.72	-$15.20M	-$0.57	-0.78

Is CLAQ or EKSO more profitable?

CleanTech Acquisition has a net margin of 0.00% compared to Ekso Bionics' net margin of -62.95%. CleanTech Acquisition's return on equity of -7.24% beat Ekso Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CleanTech Acquisition	N/A	-7.24%	0.33%
Ekso Bionics	-62.95%	-83.09%	-39.03%

Does the MarketBeat Community favor CLAQ or EKSO?

Ekso Bionics received 324 more outperform votes than CleanTech Acquisition when rated by MarketBeat users. However, 100.00% of users gave CleanTech Acquisition an outperform vote while only 54.17% of users gave Ekso Bionics an outperform vote.

Company	Underperform	Outperform
CleanTech Acquisition	Outperform Votes 1 100.00%	Underperform Votes No Votes
Ekso Bionics	Outperform Votes 325 54.17%	Underperform Votes 275 45.83%

Does the media favor CLAQ or EKSO?

In the previous week, Ekso Bionics had 7 more articles in the media than CleanTech Acquisition. MarketBeat recorded 7 mentions for Ekso Bionics and 0 mentions for CleanTech Acquisition. Ekso Bionics' average media sentiment score of 0.54 beat CleanTech Acquisition's score of 0.00 indicating that Ekso Bionics is being referred to more favorably in the news media.

Company	Overall Sentiment
CleanTech Acquisition	Neutral
Ekso Bionics	Positive

Do analysts rate CLAQ or EKSO?

Ekso Bionics has a consensus target price of $5.00, indicating a potential upside of 1,031.22%. Given Ekso Bionics' stronger consensus rating and higher possible upside, analysts clearly believe Ekso Bionics is more favorable than CleanTech Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CleanTech Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ekso Bionics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Do insiders and institutionals have more ownership in CLAQ or EKSO?

71.7% of CleanTech Acquisition shares are held by institutional investors. Comparatively, 6.4% of Ekso Bionics shares are held by institutional investors. 6.1% of Ekso Bionics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Ekso Bionics beats CleanTech Acquisition on 8 of the 14 factors compared between the two stocks.